Dostarlimab
- Generic Name
- Dostarlimab
- Brand Names
- Jemperli
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2022215-59-2
- Unique Ingredient Identifier
- P0GVQ9A4S5
- Background
Dostarlimab is an IgG humanized monoclonal antibody targeted against the human programmed death receptor-1 (PD-1). PD-1 receptors are found on T-cells and, when activated, serve to inhibit immune responses - some cancers leverage this system by overexpressing PD-1 ligands, thereby effectively inhibiting the anti-tumor immune response that would typically att...
- Indication
Dostarlimab-gxly is indicated for the treatment of adult patients with mismatch repair deficient (dMMR) recurrent or advanced endometrial cancer that has progressed despite ongoing or prior treatment with a platinum-containing chemotherapy regimen.
...
- Associated Conditions
- Advanced Microsatellite Instability High Endometrial Carcinoma, Advanced Mismatch Repair-deficient (dMMR) Endometrial Cancer, Advanced Mismatch repair deficient (dMMR) solid tumors, Recurrent Microsatellite Instability (MSI)-High Endometrial Cancer, Recurrent Mismatch Repair-deficient (dMMR) Endometrial Cancer, Recurrent Mismatch repair deficient (dMMR) solid tumors
- Associated Therapies
- -
A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202
- Conditions
- Interventions
- First Posted Date
- 2023-10-02
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 360
- Registration Number
- NCT06062420
- Locations
- 🇹🇷
GSK Investigational Site, Izmir, Turkey
Watch-and-Wait Approach With Dostarlimab in Localized dMMR/MSI-H Gastric Cancer: GERCOR Phase II Study
- First Posted Date
- 2023-09-28
- Last Posted Date
- 2024-02-05
- Target Recruit Count
- 59
- Registration Number
- NCT06059495
- Locations
- 🇫🇷
CHRU Lille, Lille, France
🇫🇷Hôpital Saint Antoine, Paris, France
A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENGOT-ov80 Study)
- First Posted Date
- 2023-09-05
- Last Posted Date
- 2024-07-23
- Lead Sponsor
- Yonsei University
- Target Recruit Count
- 198
- Registration Number
- NCT06023862
- Locations
- 🇰🇷
Bundang Seoul National University Hospital, Seongnam-si, Korea, Republic of
🇰🇷Severance Hospital, Yonsei Health System, Seoul, Korea, Republic of
🇰🇷Asan Medical Center, Seoul, Korea, Republic of
PREventing Second Cancers With DOSTARlimab
- Conditions
- Interventions
- First Posted Date
- 2023-05-11
- Last Posted Date
- 2024-07-15
- Lead Sponsor
- Centre Leon Berard
- Target Recruit Count
- 400
- Registration Number
- NCT05855811
- Locations
- 🇫🇷
Institut Claudius Regaud, Toulouse, France
🇫🇷Centre Léon Bérard, Lyon, France
🇫🇷Centre François Baclesse, Caen, France
Phase I Trial Testing the Safety and Tolerability of Chemoradiation Followed by Chemotherapy + Dostarlimab for Stage IIIC, Node Positive, Endometrial Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-04-19
- Last Posted Date
- 2024-06-04
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 21
- Registration Number
- NCT05819892
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Two-cohort Study of Niraparib and Dostarlimab Plus (Chemo)RadIotherapy in Locally-Advanced Head and Neck Squamous Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2023-03-24
- Last Posted Date
- 2024-02-20
- Target Recruit Count
- 34
- Registration Number
- NCT05784012
- Locations
- 🇪🇸
Complejo Hospitalario de Navarra, Pamplona, Navarra, Spain
🇪🇸Institut Catalá d'Oncologia (ICO) Hospitalet, Hospitalet de Llobregat, Cataluña, Spain
🇪🇸Institut Catalá d'Oncologia (ICO) BADALONA, Badalona, Cataluña, Spain
Study to Evaluate the Safety and Efficacy of TSR-042, Bevacizumab, and Niraparib in Participants With Recurrent Ovarian Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-03-02
- Last Posted Date
- 2023-04-21
- Lead Sponsor
- Tesaro, Inc.
- Target Recruit Count
- 41
- Registration Number
- NCT05751629
- Locations
- 🇺🇸
GSK Investigational Site, Oklahoma City, Oklahoma, United States
DOstarlimab in Patients With Recurrent or dMMR/MSI-H Endometrial Cancer
- First Posted Date
- 2023-02-15
- Last Posted Date
- 2024-02-23
- Target Recruit Count
- 100
- Registration Number
- NCT05728814
- Locations
- 🇪🇸
Hospital Arnau de Vilanova, Valencia, Comunidad Valenciana, Spain
A Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal Cancer
- First Posted Date
- 2023-02-10
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 150
- Registration Number
- NCT05723562
- Locations
- 🇬🇧
GSK Investigational Site, Sutton, United Kingdom
Phase II Trial of the PARP Inhibitor Niraparib and PD-1 Inhibitor Dostarlimab in Patients With Advanced Cancers With Active Progressing Brain Metastases (STARLET)
- First Posted Date
- 2023-01-26
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 120
- Registration Number
- NCT05700721
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.